Formulary classification (such as, Antidepressants, Antipsychotic agents, Opiate agonists)  Generic and brand name of drugs  Quantity (e.g., 60 pills), dosage (e.g., 50 mg) and days of supply (e.g., 5 days)
April 1990 to March 2015
Vital Statistics death file
 Dates and causes of death (diagnostic codes) April 1990 to March 2015
In the current paper, we chose time-to-event/ survival analysis since our outcome of interest (hospital admission) was not only the occurrence of an event, but also when the event occurred. Moreover, censoring was another important consideration, in selecting time-to-event analysis. In the presence of censoring, exact time-to-event is undeterminable. Traditional regression analysis is not well equipped to incorporate both the occurrence of an event and time-to-event as an outcome. In addition, our analysis was complicated due to the recurrent nature of the outcome variable and the time-varying (values change over time) nature of the primary independent variable (methadone status: medicated vs. non-medicated period). Data set-up for survival analysis with time-varying covariates is an important consideration in conducting the Cox regression. The time-varying covariates can be incorporated in the time-to-event analysis by subdividing the follow-up time into intervals/segments. This data structure procedure is referred to as counting process (CP). This process essentially subdivides an individual's entire time at risk (follow-up time) into smaller time segments to absorb the change of values of the time-dependent covariates, resulting in multiple observations per participant.
Another important consideration in constructing the Cox regression model was understanding actual time at risk. Since our outcome was recurrent hospitalizations, once participants were admitted to hospital, they were not at risk for re-hospitalization until their discharge. To account for this phenomenon, time during hospitalization (hospital days) was excluded from the time at risk. This document is intended to illustrate how time intervals including actual time at risk for methadone were constructed and accounted for in the Cox regression model. We have chosen five hypothetical participants to describe this procedure. eTable 3 presents individual time intervals for methadone without considering the event of interest (outcome) and actual time at risk while eTable 4 only presents the event time. eTable 5 illustrates the framework of analytic data incorporating the outcome and time at risk.
Individual time intervals were calculated using pharmacy filing transaction dates. If a participant filled their methadone prescription consistently (no gap in pharmacy transactions dates) for a period of time, this was treated as a single interval/episode and considered as a medicated period (methadone was dispensed). If the participant didn't fill a prescription for a period of time (gap in pharmacy transaction dates), the interval was considered a non-medicated period (methadone was not dispensed). Participants were expected to alternate between medicated and non-medicated periods throughout follow-up. . This participant had a few more medicated and non-medicated episodes until censoring (study end, March 31, 2015). In total, participant A had twelve time-intervals: six medicated and six non-medicated.
However, participant A (eTable 4 & eTable 5) experienced an event (hospital admission) at 85 days of follow-up during a medicated time-interval (interval # 3) and was released from hospital at 89 days of follow up during the same medicated time-interval (interval # 3). Once participants were in hospital, they were not at risk for re-hospitalization until discharge. Participant A stayed in hospital for four days which was excluded from the follow-up time to estimate actual time at risk. To account for this phenomenon (event time & length of stay), interval # 3 (spanning 58 to 147 days) for participant A was split into three time time-span records (eTable 5): 58 to 85 days (to specify the event time which occurred at 85 days), 85 to 89 days (to specify the time span in hospital) and 89 to 147 days (to specify the end of interval # 3). The time-span 85 to 89 days was not considered as a time at risk (highlighted blue) and was excluded during the Cox regression analysis. Participant A had no further events until censoring. Total follow-up time for participant A was 454 days (Jan 1, 2014 to Mar 31, 2015) while time at risk was 450 days (follow-up time -length of stay in hospital). The overall event (hospitalization) rate (eTable 6) for this participant was 1/450 (0.8 per person-year). Since participant A experienced an event during a medicated time-interval, the event rate for medicated periods was 1/256 (1.4 per person-year) and for non-medicated periods was 0/194 (0.0 per person-year).
Participant B initiated methadone on 10-Sep-14 and was censored on 10-Dec-14 (before study end) due to death. This participant contributed only 91 analysis-days, mostly medicated time (84 days vs. 7 days) with 11 time-intervals. Since participant B didn't experience any events, the event (hospitalization) rate was zero for all instances (overall, medicated and non-medicated period). 11 -Among 404 admissions, the distribution by four-digit diagnostic codes was as follows: F150: 45 (11.1%); F151: 43 (10.6%); F152: 39 (9.7%); F153: 9 (2.2%); F155: 260 (64.4%); F156: < 5; F158: < 5; F159: < 5. 12 -The 505 (3.7%) admissions related to Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth, and the puerperium were excluded from the MED top 5 categories presented above 13 -Among 905 admissions, the distribution by specific diagnostic codes was as follows: L0300: 20 (2.2%); L0301: < 5; L0310: 239 (26.4%); L0311: 553 (61.1%); L032: 34 (3.8%); L0330: < 5; L0331: < 5; L0333: < 5; L0334: < 5; L0335: < 5; L0336: < 5; L0339: < 5; L038: 19 (2.1%); L039: 10 (1.1%). -This table includes 
